Aventis Sues Teva Over ANDA For Generic Actonel
Aventis, a part of French drugs group Sanofi-Synthelabo, said it filed the lawsuit in response to Teva’s Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for a generic version of the drug. Teva filed its application with the FDA last month, according to Aventis.
Teva argues that its generic version would not infringe on the Actonel patents held in the US by Aventis and...
To view the full article, register now.